- 著者
- Kana Kurokawa Munechika Hara Shin-ichiro Iwakami Takuya Genda Naoko Iwakami Yosuke Miyashita Masahiro Fujioka Shinichi Sasaki Kazuhisa Takahashi
- 出版者
- The Japanese Society of Internal Medicine
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.58, no.22, pp.3283-3287, 2019-11-15 (Released:2019-11-15)
- 参考文献数
- 23
- 被引用文献数
- 13 15
The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity. Despite the frequency of hepatotoxicity, there is only limited information available regarding the pathophysiology and treatment. We herein report a 48-year-old man with lung adenocarcinoma who was treated with pembrolizumab and developed cholestatic liver injury. In this case, the importance of evaluating the histology of hepatotoxicity and the effectiveness of ursodeoxycholic acid for cholestatic liver injury is indicated.
1 0 0 0 OA Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer
- 著者
- Kyohei Misawa Hajime Yasuda Hironari Matsuda Munechika Hara Tomonori Ochiai Daisuke Koyama Hina Takano Noriaki Iwao Michiaki Koike
- 出版者
- The Japanese Society of Internal Medicine
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.61, no.22, pp.3421-3424, 2022-11-15 (Released:2022-11-15)
- 参考文献数
- 24
- 被引用文献数
- 3
Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxical exacerbation of neoplasms, referred to as "hyperprogressive disease," has been reported in a proportion of patients treated with anti-programmed cell death-1 (PD-1)/PD-1 ligand (PD-L1) blockade. We herein report a case of acute adult T-cell leukemia (ATL) that developed shortly after the administration of nivolumab, a PD-1 inhibitor, to treat non-small-cell lung cancer. There were no signs of ATL before the administration of nivolumab, and seropositivity for human T-cell leukemia virus type-1 (HTLV-1) was confirmed after the development of acute ATL. We speculate that nivolumab likely contributed to the development of acute ATL.